Heather L. Platt

Internal Medicine

180 Fort Washington Ave # 6
New York, NY 10032

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).

A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).

Journal: Human vaccines & immunotherapeutics

Published: June 23, 2026

Corrigendum to "A phase 3 randomized trial (STRIDE-9) to evaluate the safety, tolerability, and immunogenicity of V116, a population-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve Japanese adults ≥65 years of age" [Vaccine 62 (2025) 127456].

Corrigendum to "A phase 3 randomized trial (STRIDE-9) to evaluate the safety, tolerability, and immunogenicity of V116, a population-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve Japanese adults ≥65 years of age" [Vaccine 62 (2025) 127456].

Journal: Vaccine

Published: September 08, 2025

A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18-64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8.

A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18-64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: July 25, 2025

Correction: Feemster et al. Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development. Vaccines 2024, 12, 974.

Correction: Feemster et al. Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development. Vaccines 2024, 12, 974.

Journal: Vaccines

Published: June 25, 2025

Low Intrinsic Killing Activity and no Impact of Its Positivity on Phase 3 Pneumococcal Vaccine Adult Studies.

Low Intrinsic Killing Activity and no Impact of Its Positivity on Phase 3 Pneumococcal Vaccine Adult Studies.

Journal: The Journal of infectious diseases

Published: June 04, 2025

Cross reactivity within pneumococcal serogroups 6 and 15 following adult vaccination with pneumococcal conjugate vaccine V116.

Cross reactivity within pneumococcal serogroups 6 and 15 following adult vaccination with pneumococcal conjugate vaccine V116.

Journal: Communications medicine

Published: May 01, 2025

A phase 3, randomized trial to evaluate lot-to-lot consistency of V116, an adult-specific pneumococcal conjugate vaccine (STRIDE-4).

A phase 3, randomized trial to evaluate lot-to-lot consistency of V116, an adult-specific pneumococcal conjugate vaccine (STRIDE-4).

Journal: Med (New York, N.Y.)

Published: January 16, 2025

A phase 3 randomized trial (STRIDE-9) to evaluate the safety, tolerability, and immunogenicity of V116, a population-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve Japanese adults ≥65 years of age.

A phase 3 randomized trial (STRIDE-9) to evaluate the safety, tolerability, and immunogenicity of V116, a population-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve Japanese adults ≥65 years of age.

Journal: Vaccine

Published: January 15, 2025

A Phase 3 Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Vaccine, Compared with PPSV23, in Adults ≥50 Years of Age (STRIDE-10).

A Phase 3 Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Vaccine, Compared with PPSV23, in Adults ≥50 Years of Age (STRIDE-10).

Journal: Vaccines

Published: January 13, 2025

Safety, tolerability, and immunogenicity of an adult-specific pneumococcal conjugate vaccine, V116, in people living with HIV (STRIDE-7): a two-part, parallel-group, randomised, active comparator-controlled, international, phase 3 trial.

Safety, tolerability, and immunogenicity of an adult-specific pneumococcal conjugate vaccine, V116, in people living with HIV (STRIDE-7): a two-part, parallel-group, randomised, active comparator-controlled, international, phase 3 trial.

Journal: The lancet. HIV

Published: January 06, 2025

Indirect protection in adults ≥18 years of age from pediatric pneumococcal vaccination: a review.

Indirect protection in adults ≥18 years of age from pediatric pneumococcal vaccination: a review.

Journal: Expert review of vaccines

Published: October 22, 2024

A phase 3 randomized, double-blind clinical study to evaluate the safety and immunogenicity of V116 when administered concomitantly with influenza vaccine in adults 50 years of age or older.

A phase 3 randomized, double-blind clinical study to evaluate the safety and immunogenicity of V116 when administered concomitantly with influenza vaccine in adults 50 years of age or older.

Journal: Vaccine

Published: September 13, 2024

Showing 1-12 of 38

Last Updated: 09/26/2026